BAY1128688

DRUG2 trials

Sponsors

Bayer

Conditions

Endometriosis

Phase 1

Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women

CompletedNCT02434640

BayerEndometriosis

Start: 2015-04-30End: 2016-04-30Updated: 2016-05-19

Phase 2

A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best

TerminatedNCT03373422

BayerEndometriosis

Start: 2017-11-30End: 2018-10-22Updated: 2019-10-03

Related Papers

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.

2023-07-096 citations

Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study

European Journal of Endocrinology2023-06-088 citations